Offshore generics makers eye biosimilars

Chinese and Indian generics makers say they are on the verge of selling cheaper copies of complex biotech medicines. They may enter the market as soon as next year, thanks to huge investments in biotech plants. The New York Times anticipates a transformation of care for patients in much of the world in addition to a counterattack by Big Pharma. Story

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.